Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Psychopharmacology bulletin

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 7831464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serotonin-selective antidepressants.

  2009cited by this paper
• Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine

  2005cited by this paper
• Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

  2004cited by this paper
• Fluvoxamine-tricyclic antidepressant interaction

  2004cited by this paper
• Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.

  1994cited by this paper
• Debrisoquin oxidation genotype and susceptibility to lung cancer

  1994cited by this paper
• Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.

  1994cited by this paper
• The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and Nomenclature

  1993cited by this paper
• Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

  1993cited by this paper
• Inhibition by fluoxetine of cytochrome P450 2D6 activity

  1993cited by this paper
• Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

  1993cited by this paper
• The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

  1992cited by this paper
• The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer.

  1992cited by this paper
• Tricyclic antidepressant-induced seizures and plasma drug concentration.

  1992cited by this paper
• Interaction Between Fluvoxamine and Imipramine/Desipramine in Four Patients

  1992cited by this paper
• Inhibitors of imipramine metabolism by human liver microsomes.

  1992cited by this paper
• Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.

  1992cited by this paper
• Debrisoquine hydroxylation in Parkinson's disease

  1992cited by this paper
• Fluoxetine impairs clearance of alprazolam but not of clonazepam

  1992cited by this paper
• Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence.

  1991cited by this paper
• Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness.

  1991cited by this paper
• The P450 Superfamily: Update on New Sequences, Gene Mapping, and Recommended Nomenclature

  1991cited by this paper
• Central Nervous System Toxicity of Tricyclic Antidepressants: Phenomenology, Course, Risk Factors, and Role of Therapeutic Drug Monitoring

  1990cited by this paper
• Molecular genetics and the future of pharmacogenetics.

  1990cited by this paper
• Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype

  1989cited by this paper
• N-acetyltransferase.

  1989cited by this paper
• Interaction of fluoxetine with tricyclic antidepressants.

  1988cited by this paper
• McN-5652: a highly potent inhibitor of serotonin uptake.

  1988cited by this paper
• The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam

  1988cited by this paper
• MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

  1987cited by this paper
• Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.

  1987cited by this paper
• Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.

  1985cited by this paper
• Polymorphic hydroxylation of perhexiline maleate in man.

  1984cited by this paper
• Acetylator Phenotype and Lupus Erythematosus

  1981cited by this paper
• Inhibition of drug metabolism by fluoxetine.

  1976cited by this paper
• Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects

  1972cited by this paper
• Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis.

  1954cited by this paper

• Therapeutic Drug Monitoring of Antidepressants.

  2019cites this paper
• Paroxetine-induced Hypoglycemia in Type 2 Diabetic Patient

  2016cites this paper
• Anticipating and Minimizing Drug Interactions in a Drug Discovery and Development Setting: An Industrial Perspective

  2010cites this paper
• Links among Paroxetine-Induced Sexual Dysfunctions, Gender, and CYP2D6 Activity

  2007cites this paper
• Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions

  2006cites this paper
• Akutes Nierenversagen im Rahmen einer Grapefruitdiät

  2006cites this paper
• Pharmacogenetics of psychotropic drug response.

  2004cites this paper
• Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.

  2003cites this paper
• Obtaining Informed Consent When a Profession Labels Itself as Providing Treatment for Mental Illness

  2003cites this paper
• Psychopharmakotherapie: pharmakologische Grundlagen

  2003cites this paper
• Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis.

  2003cites this paper
• Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes.

  2002cites this paper
• An Overview of The Definition and Management of Treatment-Resistant Depression

  2002cites this paper
• Molecular and Cellular Events Regulating Dopamine Neuron Survival

  2002cites this paper
• Relationship Between CYP 2D6 Metabolic Status and Sexual Dysfunction in Paroxetine Treatment

  2002cites this paper
• Dopamine in the CNS II

  2002cites this paper
• Review of sertraline and its clinical applications in psychiatric disorders

  2001cites this paper
• Sertraline-Induced Hypoglycemia

  2001cites this paper
• Prediction of Metabolic Drug Interactions: Quantitative or Qualitative?

  2001cites this paper
• Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder.

  2001cites this paper
• Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial.

  2000cites this paper
• Pharmacokinetics of selective serotonin reuptake inhibitors.

  2000cites this paper
• Pharmacokinetics and pharmacodynamics of the selective serotonin reuptake inhibitors, fluoxetine and paroxetine, during pregnancy and the nursing period

  2000cites this paper
• Problems with currently available antidepressants.

  2000influential citation
• Sense and nonsense in the prediction of drug-drug interactions.

  2000cites this paper
• Metabolism of Some “Second”– and “Fourth”–Generation Antidepressants: Iprindole, Viloxazine, Bupropion, Mianserin, Maprotiline, Trazodone, Nefazodone, and Venlafaxine

  1999cites this paper
• Antipsychotics from theory to practice: integrating clinical and basic data.

  1999cites this paper
• Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

  1999cites this paper
• Non-steroidal Anti-inflammatory Drugs with Adverse Psychiatric Reactions: Five Case Reports

  1999cites this paper
• SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment

  1998cites this paper
• Distribution of paroxetine in three postmortem cases.

  1998cites this paper
• Risks and Benefits of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression

  1998cites this paper
• Het cytochroom P450 enzymsysteem: wat is de relevantie voor de praktijk? Deel II, interacties.

  1998cites this paper
• Psychotropic drug metabolism in the cancer patient: clinical aspects of management of potential drug interactions

  1998cites this paper
• Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping

  1998cites this paper
• New atypical antipsychotic medications.

  1998cites this paper
• Metabolism of the Newer Antidepressants

  1998cites this paper
• Fluoxetine tenth anniversary update: the progress continues.

  1997cites this paper
• Is Once Weekly Administration of Antidepressants Feasible?

  1997cites this paper
• Treatment of major depression: selection of initial drug.

  1997cites this paper
• Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.

  1997cites this paper
• The effect of paroxetine on thiothixene pharmacokinetics

  1997cites this paper
• Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.

  1997cites this paper
• Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology.

  1997cites this paper
• [Effect of antidepressant drugs on cytochrome P-450 isoenzymes and their clinical relevance: differential profile].

  1997cites this paper
• Newer antidepressants and the cytochrome P450 system.

  1996cites this paper
• Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.

  1996cites this paper
• Cytochromes and Psychotropic Drug Interactions

  1996cites this paper
• The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin

  1996cites this paper
• Cytochrome P450: genetic polymorphism and drug interactions.

  1996cites this paper
• The role of cytochrome P450 2D6 in the metabolism of moclobemide.

  1996cites this paper
• CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects.

  1996cites this paper
• Evaluating the Clinical Significance of Drug Interactions: A Systematic Approach

  1996cites this paper
• Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing.

  1996cites this paper
• Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system.

  1996cites this paper
• Antidepressant Options: Venlafaxine in Perspective

  1996cites this paper
• Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance.

  1996cites this paper
• Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors

  1996cites this paper
• Pharmacology and pharmacokinetics of citalopram and other SSRIs

  1996cites this paper
• Drug-Drug Interactions Involving Antidepressants: Focus on Venlafaxine

  1996cites this paper
• Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors

  1996cites this paper
• Use of serotonin selective reuptake inhibitors in geriatric depression.

  1996cites this paper
• Critical issues in the treatment of affective disorders

  1995cites this paper
• Specific binding of [3H]imipramine indicates the presence of a specific serotonin transport system on endothelial cells of porcine brain.

  1995cites this paper
• Withdrawal syndromes after paroxetine and sertraline discontinuation.

  1995cites this paper
• Interactions and drug-metabolizing enzymes.

  1995cites this paper
• Antidepressant Drug Interactions and the Cytochrome P450 System

  1995cites this paper